Pilot Study of a Novel Type of CT Scan to Assess Treatment Response During Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer

Pilot Study of Dual-Energy Computed Tomography in Stage III Non-Small Cell Lung Cancer

NCT02053285•Rush University Medical Center

Summary

Dual-energy CT (DECT) provides information on the blood volume in tumors and lymph nodes. As tumors respond to treatment, preliminary data suggests that the blood volumes changes as well. Investigators are therefore using DECT to test whether it can be used on radiation treatment to rapidly assess response to treatment.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients aged greater than 18 years with a diagnosis of stage III non-small cell lung cancer.
•Planned treatment with either definitive chemoradiotherapy or preoperative chemoradiotherapy followed by surgical resection.
•PET-CT study within 4 weeks of next available DECT study.
•Patients must have measurable primary and nodal disease, defined by at least one lesion (primary and lymph node) greater than 1 cm.
•Kidney function sufficient to tolerate iodine-based CT contrast.
•No allergy to iodine-based contrast.
•Ability to understand and the willingness to sign informed consent.

Exclusion Criteria

•Participants with a prior history of thoracic radiotherapy.
•Participants may not be receiving any other study agents.
•Inability to tolerate CT contrast
•Pregnant women are excluded from this study because radiotherapy has the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk of adverse events in nursing infants secondary to treatment of the mother with radiotherapy, breastfeeding should be discontinued if the mother is treated with radiotherapy. These potential risks may also apply to other agents used in this study.

Locations (1)

Rush University Medical Center

Chicago, Illinois, United States

Key Dates

Start Date

January 1, 2014

Primary Completion Date

May 1, 2019

Completion Date

February 20, 2020

Last Updated

September 23, 2022

Enrollment

ACTUAL participants

Conditions

Non-small Cell Lung Cancer Stage III

Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer

NCT07250477

Non-small Cell Lung Cancer Stage IIICNon-small Cell Lung Cancer Stage IV+3 more

View study

RECRUITINGPHASE1/PHASE2

AK129 Combination Therapy for Advanced Solid Tumors

NCT06943820

Non-small Cell Lung Cancer Stage IIIB/IVHead and Neck Squamous Cell Carcinoma (HNSCC)+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 23, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Pilot Study of a Novel Type of CT Scan to Assess Treatment Response During Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer

Inclusion Criteria

Exclusion Criteria

Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer

AK129 Combination Therapy for Advanced Solid Tumors

Alectinib Pharmacokinetic in Patients With NSCLC

Sequential Chemo-immunotherapy Plus Thoracic Radiotherapy for Elderly And/or Frail Stage III Non-small-cell Lung Cancer

Xingbai Ji Formula Combined with Chemotherapy and Sintilimab in Metastatic Multi-Target Mutation-Negative Non-Small Cell Lung Cancer: a Clinical Trial

Survival Prolongation by Rationale Innovative Genomics